JPH05310766A - New antibiotic substance mi481-42f4-a and its produciton - Google Patents

New antibiotic substance mi481-42f4-a and its produciton

Info

Publication number
JPH05310766A
JPH05310766A JP4142045A JP14204592A JPH05310766A JP H05310766 A JPH05310766 A JP H05310766A JP 4142045 A JP4142045 A JP 4142045A JP 14204592 A JP14204592 A JP 14204592A JP H05310766 A JPH05310766 A JP H05310766A
Authority
JP
Japan
Prior art keywords
shoulder
antibiotic
culture
medium
methanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP4142045A
Other languages
Japanese (ja)
Other versions
JP3107455B2 (en
Inventor
Tomio Takeuchi
富雄 竹内
Masa Hamada
雅 濱田
Hiroshi Osanawa
博 長縄
Hironobu Iinuma
寛信 飯沼
Kazuo Shimanaka
一夫 嶋中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microbial Chemistry Research Foundation
Original Assignee
Microbial Chemistry Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbial Chemistry Research Foundation filed Critical Microbial Chemistry Research Foundation
Priority to JP04142045A priority Critical patent/JP3107455B2/en
Publication of JPH05310766A publication Critical patent/JPH05310766A/en
Application granted granted Critical
Publication of JP3107455B2 publication Critical patent/JP3107455B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PURPOSE:To obtain a new antibiotic substance M1481-42F4-A having antimicrobial activity of strongly inhibiting the growth of Gram-positive bacteria and multi-drug resistant germs and a method for producing the antibiotic substance. CONSTITUTION:The antibiotic substance MI481-42F4-A is separated and collected from a culture solution of a strain belonging to the genus Amycolatopsis. This antibiotic substance MI481-42F4-A is obtained as a colorless powdery basic substance having 294-295C melting point (decomposition) and the molecular formula C50H51O8N15S6.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は新規抗生物質MI481
−42F4−A及びその製造方法に関する。
The present invention relates to a novel antibiotic MI481.
-42F4-A and its manufacturing method.

【0002】[0002]

【従来の技術】微生物の生産する抗生物質はこれまでに
数多く発見されており、細菌感染症の治療に広く用いら
れている。
2. Description of the Related Art A large number of antibiotics produced by microorganisms have been discovered so far and are widely used for treating bacterial infections.

【0003】[0003]

【発明が解決しようとする課題】細菌感染症の治療にお
いては耐性菌の出現が避けられず、耐性菌に有効な新し
い抗生物質が絶えず求められている。
In the treatment of bacterial infections, the emergence of resistant bacteria is unavoidable, and new antibiotics effective against resistant bacteria are constantly being sought.

【0004】[0004]

【課題を解決するための手段】本発明者らは、研究の結
果、アミコラトプシス属に属する菌株の培養液から新規
な抗生物質MI481−42F4−Aを収得することに
成功し、この物質が抗菌活性を有することを知見した。
As a result of research, the present inventors succeeded in obtaining a novel antibiotic MI481-42F4-A from a culture solution of a strain belonging to the genus Amycolatopsis, and this substance was found to be It was found to have antibacterial activity.

【0005】従って、第1の本発明によれば、下記の特
性: (1) 色と形状:無色粉末 (2) 融点:294−295℃(分解) (3) 元素分析:C 49.46%,H 4.79%,N
16.76%, O 12.23%,S 15.72% (4) 紫外線吸収スペクトル: ラムダ最大(nm) メタノール 203 309 221 350(肩) 245(肩) メタノール−塩酸 205 308 222 353(肩) 250(肩) メタノール−水酸化ナトリウム 205 310 221 353(肩) 250(肩) (5) 赤外線吸収スペクトル(KBr法):3300,3
120,2980,1660,1550,1500,1
250,990,940,760 cm-1 (6) 安定性:室温、pH2〜9で安定 (7) 比旋光度:〔α〕D 28=+133°(c 0.74
5,ジメチルスルホキシド) (8) 酸性、中性、塩基性の区分:塩基性物質 (9) 分子量:1182.44 (10)分子式:C50518 156 を有することを特徴とする新規な抗生物質MI481−
42F4−Aが提供される。
Therefore, according to the first invention, the following characteristics are provided: (1) Color and shape: colorless powder (2) Melting point: 294-295 ° C. (decomposition) (3) Elemental analysis: C 49.46% , H 4.79%, N
16.76%, O 12.23%, S 15.72% (4) Ultraviolet absorption spectrum: lambda maximum (nm) methanol 203 309 221 221 350 (shoulder) 245 (shoulder) methanol-hydrochloric acid 205 308 222 222 353 (shoulder) 250 (shoulder) methanol-sodium hydroxide 205 310 221 353 (shoulder) 250 (shoulder) (5) Infrared absorption spectrum (KBr method): 3300,3
120, 2980, 1660, 1550, 1500, 1
250,990,940,760 cm -1 (6) Stability: Stable at room temperature and pH 2-9 (7) Specific rotation: [α] D 28 = + 133 ° (c 0.74
5, dimethylsulfoxide) (8) Acidic, neutral, basic classification: basic substance (9) molecular weight: 1182.44 (10) molecular formula: C 50 H 51 O 8 N 15 S 6 New antibiotic MI481-
42F4-A is provided.

【0006】更に、第2の本発明によれば、アミコラト
プシス(Amycolatopsis )属に属するMI481−42
F4−A生産菌を培養し、その培養物から抗生物質MI
481−42F4−Aを分離採取することを特徴とする
抗生物質MI481−42F4−Aの製造法が提供され
る。
Further, according to the second aspect of the present invention, MI481-42 belonging to the genus Amycolatopsis.
The F4-A producing bacterium is cultivated and the antibiotic MI is extracted from the culture.
There is provided a method for producing the antibiotic MI481-42F4-A, which comprises separating and collecting 481-42F4-A.

【0007】本発明の方法で用い得るアミコラトプシス
属に属するMI481−42F4−A生産菌の1例とし
ては、本発明者らによって昭和62年6月東京都練馬区
で採取した土壌試料より分離した菌株アミコラトプシス
・エスピー(Amycolatopsissp. )MI481−42F
4がある。この菌株の菌学的性状は次のとおりである。
One example of the MI481-42F4-A-producing bacterium belonging to the genus Amycolatopsis that can be used in the method of the present invention is isolated from a soil sample collected by the present inventors in Nerima Ward, Tokyo in June 1987. Strain Amycolatopsis sp. MI481-42F
There is 4. The mycological properties of this strain are as follows.

【0008】MI481−42F4株の菌学的性状 1.形態 よく分枝した基生菌糸は、しばしばジグザグ状を呈し、
また分断が認められる。気菌糸は直状あるいは不規則な
曲状で、分断を認め、円筒形の胞子を形成する。胞子の
大きさは約0.6〜0.7×1.7〜1.2ミクロン
で、表面は平滑である。らせん形成、輪生枝および胞子
のうは認められない。
Mycological properties of MI481-42F4 strain 1. Morphology Well-branched basal hyphae often have a zigzag shape,
In addition, division is recognized. The aerial hyphae are straight or irregularly curved, with fragmentation, forming cylindrical spores. The spore size is approximately 0.6-0.7 x 1.7-1.2 microns and the surface is smooth. No helix formation, limbus or sporangia are observed.

【0009】2.各種培地における生育状態 色の記載について[ ]内に示す標準は、コンティナー
・コーポレーション・オブ・アメリカのカラー・ハーモ
ニー・マニュアル(Container Corporation ofAmerica
のcolor harmony manual)を用いた。
2. Regarding the description of the growth state color in various media, the standard shown in [] is the Container Harmony Manual (Container Corporation of America).
Color harmony manual).

【0010】(1)シュクロース・硝酸塩寒天培地(3
0℃培養) うす黄[1 ea, Canary Yellow ]の発育上に、白の気菌
糸をうっすらと着生し、溶解性色素は認められない。
(1) Sucrose / nitrate agar medium (3
(0 ° C culture) On the development of light yellow [1 ea, Canary Yellow], white aerial hyphae were slightly settled and no soluble pigment was observed.

【0011】(2)グルコース・アスパラギン寒天培地
(30℃培養) 黄[1 1/2 ia, Sunlight Yellow ]の発育上に、うす黄
[1 ca, Pale Yellow]の気菌糸を着生し、溶解性色素
はわずかに黄色味を帯びる。
(2) Glucose / asparagine agar medium (30 ° C. culture) On the development of yellow [1 1/2 ia, Sunlight Yellow], aerial mycelia of pale yellow [1 ca, Pale Yellow] are grown and dissolved. The sex pigment is slightly yellowish.

【0012】(3)グリセリン・アスパラギン寒天培地
(ISP−培地5、30℃培養) うす黄[1 1/2 ga, Butter Yellow ]の発育上に、うす
黄[1 1/2 ca, Cream]の気菌糸を着生し、溶解性色素
はわずかに黄色味を帯びる。
(3) Glycerin-asparagine agar medium (ISP-medium 5, culture at 30 ° C.) In developing light yellow [1 1/2 ga, Butter Yellow], light yellow [1 1/2 ca, Cream] was added. The aerial hyphae are settled, and the soluble pigment is slightly yellowish.

【0013】(4)スターチ・無機塩寒天培地(ISP
−培地4、30℃培養) うす黄[1 1/2 ic, Lt Antique Gold*2gc, Bamboo ]の
発育上に白の気菌糸をうっすらと着生し、溶解性色素は
認められない。
(4) Starch / inorganic salt agar medium (ISP
-Medium 4, culture at 30 ° C) White aerial hyphae grow slightly on the development of light yellow [1 1/2 ic, Lt Antique Gold * 2gc, Bamboo], and no soluble pigment is observed.

【0014】(5)チロシン寒天培地(ISP−培地
7、30℃培養) 黄[1 1/2 lc, Gold]の発育上に茶白[2 ca, Lt Ivor
y]の気菌糸を着生し、溶解性色素は黄色味を帯びる。
(5) Tyrosine agar medium (ISP-medium 7, culture at 30 ° C.) For the development of yellow [1 1/2 lc, Gold], brown white [2 ca, Lt Ivor]
y] aerial hyphae are settled, and the soluble pigment becomes yellowish.

【0015】(6)栄養寒天培地(30℃培養) うす[2 gc, Bamboo]の発育上に、白の気菌糸をうっす
らと着生し、溶解性色素は認められない。
(6) Nutrient agar medium (cultivation at 30 ° C.) White aerial hyphae grow slightly on the growth of light-weight [2 gc, Bamboo], and no soluble pigment is observed.

【0016】(7)イースト・麦芽寒天培地(ISP−
培地2、30℃培養) うす黄茶[2 ne, Mastard Gold]の発育上に、白の気菌
糸を着生し、溶解性色素は認められない。
(7) Yeast-malt agar medium (ISP-
Medium 2, culture at 30 ° C) On the development of light yellow tea [2 ne, Mastard Gold], white aerial hyphae grew and no soluble pigment was observed.

【0017】(8)オートミール・寒天培地(ISP−
培地3、30℃培養) うす黄[1 1/2 ic, Lt Antique Gold ]の発育上に、白
の気菌糸をうっすらと着生し、溶解性色素はわずかに黄
色味を帯びる。
(8) Oatmeal / agar medium (ISP-
Medium 3, culture at 30 ° C) On the development of light yellow [1 1/2 ic, Lt Antique Gold], white aerial mycelium grows faintly, and the soluble pigment is slightly yellowish.

【0018】(9)グリセリン・硝酸塩寒天培地(30
℃培養) うす黄[1 ga, Lt Lemon Yellow ]の発育上に、白の気
菌糸をうっすらと着生し、溶解性色素は認められない。
(9) Glycerin / nitrate agar medium (30
(° C culture) On the development of light yellow [1 ga, Lt Lemon Yellow], white aerial hyphae were slightly settled and no soluble pigment was observed.

【0019】(10)スターチ寒天培地(30℃培養) 黄[1 la, Lemon Yellow]の発育上に、白の気菌糸をわ
ずかに着生する。溶解性色素は認められない。
(10) Starch agar medium (cultivation at 30 ° C.) White aerial mycelium slightly grows on the development of yellow [1 la, Lemon Yellow]. No soluble dye is found.

【0020】(11)リンゴ酸石灰寒天培地(30℃培
養) うす黄[1 ga. Lt Lemon Yellow ]の発育上に、白の気
菌糸をわずかに着生し、溶解性色素は認められない。
(11) Lime malate agar medium (30 ° C. culture) On the development of light yellow [1 ga. Lt Lemon Yellow], white aerial hyphae slightly colonize and no soluble pigment is observed.

【0021】(12)セルロース(ろ紙片添加合成液、3
0℃培養) 発育はうす黄、白の気菌糸を着生し、溶解性色素は認め
られない。
(12) Cellulose (synthetic solution containing filter paper pieces, 3
(0 ° C culture) Growth develops pale yellow and white aerial mycelium, and no soluble pigment is observed.

【0022】(13)ゼラチン穿刺培養 15%単純ゼラチン培地(20℃培養)では、発育はう
す黄、白の気菌糸をうっすらと着生し、溶解性色素は認
められない。グルコース・ペプトン・ゼラチン培地(2
7℃培養)の場合、発育はうす黄、気菌糸は着生せず、
溶解性色素は認められない。
(13) Gelatin stab culture In a 15% simple gelatin medium (cultured at 20 ° C.), pale yellow and white aerial hyphae grow faintly and no soluble dye is observed. Glucose / peptone / gelatin medium (2
In the case of 7 ° C culture), the growth is pale yellow, and the aerial mycelium does not settle,
No soluble dye is found.

【0023】(14)脱脂牛乳(37℃および30℃培
養) 37℃培養での生育は認められなかった。30℃培養の
場合、発育はうす黄、気菌糸は着生せず、溶解性色素も
認められない。
(14) Skim milk (37 ° C. and 30 ° C. culture) No growth was observed in 37 ° C. culture. In the case of culturing at 30 ° C., growth is pale yellow, aerial hyphae do not grow, and soluble pigments are not observed.

【0024】3.生理的性質 (1)生育温度範囲 グルコース・アスパラギン寒天培地(グルコース 1.
0%、L−アスパラギン0.05%、リン酸二カリウム
0.05%、紐寒天 3.0%、pH 7.0)を用
い、6℃、20℃、24℃、27℃、30℃、37℃、
50℃の各温度で試験した結果、6℃、37℃、50℃
を除き、そのいずれの温度でも生育し、生育至適温度は
27℃〜30℃付近と思われる。
3. Physiological properties (1) Growth temperature range Glucose / asparagine agar medium (glucose 1.
0%, L-asparagine 0.05%, dipotassium phosphate 0.05%, string agar 3.0%, pH 7.0), 6 ° C, 20 ° C, 24 ° C, 27 ° C, 30 ° C, 37 ° C,
Tested at each temperature of 50 ℃, 6 ℃, 37 ℃, 50 ℃
Except that, the optimum growth temperature seems to be around 27 ° C to 30 ° C.

【0025】(2)ゼラチンの液化(15%単純ゼラチ
ン培地、20℃培養;グルコース・ペプトン・ゼラチン
培地、27℃培養) 15%単純ゼラチン培地では培養後3日目頃より液化が
始まり、約3週間後、完了した。グルコース・ペプトン
・ゼラチン培地においては、培養後7日目頃よりわずか
に液化を認めるが進行は極めて遅く、1ヵ月間の培養で
は完了しなかった。
(2) Liquefaction of gelatin (15% simple gelatin medium, 20 ° C. culture; glucose / peptone / gelatin medium, 27 ° C. culture) In 15% simple gelatin medium, liquefaction started from about 3 days after culturing and about 3 Completed a week later. In the glucose-peptone-gelatin medium, a slight liquefaction was observed around the 7th day after the culture, but the progress was extremely slow, and the culture was not completed for one month.

【0026】(3)スターチの加水分解(スターチ・無
機塩寒天培地およびスタータ寒天培地、いずれも30℃
培養) いずれの培地においても培養後6日目頃より水解性が認
められ、その作用は中等度である。
(3) Hydrolysis of starch (starch / inorganic salt agar medium and starter agar medium, both at 30 ° C.)
Cultivation) In any medium, water-decomposability was observed around the 6th day after culturing, and its action was moderate.

【0027】(4)脱脂牛乳の凝固・ペプトン化(脱脂
牛乳、37℃および30℃培養) 37℃培養では生育が認められない。30℃培養の場
合、培養後10日頃より凝固することなくペプトン化が
始まり、約1ヵ月間の培養後に完了した。
(4) Coagulation and Peptone of Skim Milk (Skim Milk, Cultivated at 37 ° C. and 30 ° C.) Growth at 37 ° C. is not observed. In the case of culturing at 30 ° C., peptization started without coagulation from about 10 days after culturing, and was completed after culturing for about 1 month.

【0028】(5)メラニン様色素の生成(トリプトン
・イースト・ブロス、ISP−培地1;ペプトン・イー
スト・鉄寒天培地、ISP−培地6;チロシン寒天培
地、ISP−培地7;いずれも30℃培養) いずれの培地でも陰性である。
(5) Production of melanin-like pigment (tryptone yeast broth, ISP-medium 1; peptone yeast iron agar medium, ISP-medium 6; tyrosine agar medium, ISP-medium 7; both cultures at 30 ° C. ) All media are negative.

【0029】(6)炭素源の利用性(プリドハム・ゴド
リーブ寒天培地、ISP−培地9;30℃培養) D−グルコース、L−アラビノース、D−キシロース、
イノシトール、D−マンニトール、ラクトースを利用し
て発育し、シュクロースは利用しない。D−フルクトー
ス、ラムノース、ラフィノースはおそらく利用すると思
われる。
(6) Utilization of carbon source (Pridham-Godlieve agar medium, ISP-medium 9; 30 ° C. culture) D-glucose, L-arabinose, D-xylose,
It grows using inositol, D-mannitol and lactose, but does not use sucrose. D-fructose, rhamnose and raffinose are likely to be utilized.

【0030】(7)リンゴ酸石灰の溶解(リンゴ酸石灰
寒天培地、30℃培養) 培養後10日目頃より溶解性が認められ、その作用は中
等度である。
(7) Dissolution of lime malate (lime malate agar medium, culturing at 30 ° C.) Solubility was observed around 10 days after culturing, and its action was moderate.

【0031】(8)硝酸塩の還元反応(0.1%硝酸カ
リウム含有ペプトン水、ISP−培地8、30℃培養) 陽性である。
(8) Reduction reaction of nitrate (peptone water containing 0.1% potassium nitrate, ISP-medium 8, culture at 30 ° C.) is positive.

【0032】(9)セルロースの分解(ろ紙片添加合成
液、30℃培養) 6ヵ月間の観察で分解は認められない。
(9) Degradation of cellulose (synthetic solution containing filter paper pieces, culture at 30 ° C.) Degradation is not observed after 6 months of observation.

【0033】以上の性状を要約すると、MI184−4
2F4株は、その形態上、基生菌糸はしばしばジグザグ
状を呈し、分断を認める。気菌糸は直状あるいは不規則
な曲状で、分断を認め、円筒形の胞子を形成し、その表
面は平滑である。らせん形成、輪生枝及び胞子のうは認
められない。種々の培地で、うす黄〜黄の発育上に白〜
うす黄の気菌糸を着生し、溶解性色素はわずかに黄色味
を帯びるか、又は認められない。メラニン様色素の生成
は陰性、スターチの水解性は中等度、硝酸塩の還元反応
は陽性であり、蛋白分解力は中等度である。
Summarizing the above properties, MI184-4
In the 2F4 strain, the basal hypha often show a zigzag shape due to its morphology, and fragmentation is observed. The aerial mycelium is straight or irregularly curved, with fragmentation, forming cylindrical spores, and its surface is smooth. No helix formation, limbal branch or sporangium is observed. In various media, light yellow ~ white on the development of yellow ~
The pale yellow aerial hyphae are settled, and the soluble pigment is slightly yellowish or absent. The formation of melanin-like pigment is negative, the water-degradability of starch is moderate, the reduction reaction of nitrate is positive, and the proteolytic activity is moderate.

【0034】ところで、MI481−42F4株の菌体
成分は、細胞壁に含まれる2,6−ジアミノピメリン酸
がメソ型であり、全菌体中の還元糖はアラビノース、ガ
ラクトースを含むA型である。また、ミコール酸を含ま
ず、リン脂質はPH型(ホスファチジルエタノールアミ
ンを含みホスファチジルコリン及び未知のグルコサミン
含有リン脂質を含まない)、主要なメナキノンはMK−
9(H4 )であり、MK−9(H2 )も認められた。
By the way, in the bacterial cell component of the MI481-42F4 strain, 2,6-diaminopimelic acid contained in the cell wall is meso-type, and the reducing sugar in all the bacterial cells is A-type containing arabinose and galactose. In addition, it contains no mycolic acid, the phospholipid is PH type (containing phosphatidylethanolamine and does not contain phosphatidylcholine and unknown glucosamine-containing phospholipid), and the major menaquinone is MK-.
9 (H 4 ) and MK-9 (H 2 ) was also recognized.

【0035】以上の結果より、MI481−42F4株
は、アミコラトプシス(Amycolatop sis ,文献,Intern
ational Journal of Systematic Bacteriology,36
巻,29−37頁,1988年)属に属するものと考え
られる。アミコラトプシス属の既知菌種を検索すると、
アミコラトプシス・オリエンタリス(Amycolatopsis or
ientalis,文献1,同上;文献2,International Jour
nal of Systematic Bactoriology,37巻,292−2
95頁,1987年)及びアミコラトプシス・メディテ
ラネイ(Amycolatopsis mediterranei,文献1及び2,
同上)が、近縁の種としてあげられた。
[0035] From the above results, MI481-42F4 strain, Amycolatopsis (Amycolatop sis, literature, Intern
ational Journal of Systematic Bacteriology, 36
Vol., 29-37, 1988). Searching for known species of the genus Amycolatopsis,
Amycolatopsis orientalis ( Amycolatopsis or
ientalis , Reference 1, Ibid; Reference 2, International Jour
nal of Systematic Bactoriology, 37, 292-2
95, 1987) and Amycolatopsis mediterranei , 1 and 2,
Ibid.) Was listed as a closely related species.

【0036】そこで、MI481−42F4株と上記2
種の当研究所保存菌株とを実地に比較検討中である。現
時点ではMI481−42F4株をアミコラトプシス・
エスピー(Amycolatopsis sp. )MI481−42F4
とする。
Therefore, the MI481-42F4 strain and the above-mentioned 2
We are currently conducting a comparative study of the strains conserved by this institute. Currently, MI481-42F4 strain is
SP ( Amycolatopsis sp.) MI481-42F4
And

【0037】なお、MI481−42F4株を工業技術
院微生物工業技術研究所に寄託申請し、平成4年2月3
日、微工研菌寄第12739号として受託された。
The MI481-42F4 strain was applied for deposit at the Institute of Microbial Science and Technology of the Agency of Industrial Science and Technology on February 3, 1992.
It was entrusted as Japan Institute of Microbiology, No. 12739.

【0038】本発明に用いることのできる菌株は上記菌
株、その変異株をはじめ、アミコラトプシス属に属する
MI484−42F4−A生産菌のすべてが使用でき
る。
As the strain that can be used in the present invention, all of the MI484-42F4-A producing strains belonging to the genus Amycolatopsis can be used, including the above strains and mutants thereof.

【0039】本発明の抗生物質MI481−42F4−
4は、上記菌株を抗生物質MI481−42F4−A生
産に適した培地に接種し培養することにより生産され
る。培地としては、通常の放線菌の培養に用いられる栄
養源含有培地でよい。
Antibiotics of the present invention MI481-42F4-
4 is produced by inoculating the above strain into a medium suitable for producing the antibiotic MI481-42F4-A and culturing. The medium may be a nutrient-source-containing medium used for usual actinomycete culture.

【0040】栄養源としては、例えば市販されているペ
プトン、肉エキス、コーン・スティープ・リカー、綿実
粉、落花生粉、大豆粉、酵母エキス、MZ−アミン、カ
ゼイン水解物、硝酸ソーダ、硝酸アンモニウム、硫酸ア
ンモニウムなどの窒素源、及び市販されているグリセリ
ン、しょ糖、でん粉、グルコース、ガラクトース、マン
ノース、糖蜜などの炭水化物、あるいは脂肪などの炭素
源、及び食塩、リン酸塩、炭酸カルシウム、硫酸マグネ
シウムなどの無機塩を使用できる。その他必要に応じて
微量の金属塩、消泡剤としての動・植・鉱物油などを添
加することもできる。これらのものは生産菌が利用し抗
生物質MI481−42F4−Aの生産に役立つもので
あればよく、放線菌の公知の培養材料はすべて用いるこ
とができる。
Examples of nutrient sources include commercially available peptone, meat extract, corn steep liquor, cottonseed flour, peanut flour, soybean flour, yeast extract, MZ-amine, casein hydrolyzate, sodium nitrate, ammonium nitrate, Nitrogen sources such as ammonium sulfate and commercially available glycerin, sucrose, starch, glucose, galactose, mannose, molasses and other carbohydrates, or carbon sources such as fat, and inorganics such as salt, phosphate, calcium carbonate and magnesium sulfate. Salt can be used. In addition, if necessary, a trace amount of a metal salt, or an antifoaming agent such as animal / vegetable / mineral oil may be added. Any of these may be used as long as it can be used by the producing bacterium and is useful for producing the antibiotic MI481-42F4-A, and all known culture materials for actinomycetes can be used.

【0041】抗生物質MI481−42F4−Aの大量
生産には液体培養が好ましく、培養温度は抗生物質MI
481−42F4−Aを生産できる範囲で適用できる。
培養は以上述べた条件を適用しMI481−42F4−
A生産菌の性質に応じて適宜選択して行うことができ
る。
Liquid culture is preferable for mass production of the antibiotic MI481-42F4-A, and the culture temperature is the antibiotic MI.
It can be applied within the range where 481-42F4-A can be produced.
For the culture, the conditions described above were applied to MI481-42F4-
It can be performed by appropriately selecting it depending on the properties of the A-producing bacterium.

【0042】抗生物質MI481−42F4−Aは主と
して菌体中に存在しアルコール、アセトニトリル、アセ
トンなど水と混和する有機溶媒で抽出できる。菌体抽出
液よりブタノールなど比較的極性の強い水不混和性の有
機溶剤で抽出することができる。上述の抽出法に加え、
吸着クロマトグラフィー、ゲル濾過クロマトグラフィ
ー、薄層クロマトグラフィー、向流分配クロマトグラフ
ィー、高速液体クロマトグラフィーなど公知の方法を適
宜組合わせ、あるいは繰返すことによって、純粋に採取
することができる。
The antibiotic MI481-42F4-A can be extracted with an organic solvent which is mainly present in the cells and is miscible with water such as alcohol, acetonitrile and acetone. The cell extract can be extracted with a water-immiscible organic solvent having a relatively high polarity such as butanol. In addition to the above extraction method,
Pure collection can be performed by appropriately combining or repeating known methods such as adsorption chromatography, gel filtration chromatography, thin layer chromatography, countercurrent partition chromatography, and high performance liquid chromatography.

【0043】抗生物質MI481−42F4−Aの理化
学的性状は次のとおりである。
The physicochemical properties of the antibiotic MI481-42F4-A are as follows.

【0044】(1) 色と形状:無色粉末 (2) 融点:294−295℃(分解) (3) 元素分析:C 49.46%,H 4.79%,N
16.76%, O 12.23%,S 15.72% (4) 紫外線吸収スペクトル: ラムダ最大(nm) メタノール 203 309 221 350(肩) 245(肩) メタノール−塩酸 205 308 222 353(肩) 250(肩) メタノール−水酸化ナトリウム 205 310 221 353(肩) 250(肩)。
(1) Color and shape: colorless powder (2) Melting point: 294-295 ° C (decomposition) (3) Elemental analysis: C 49.46%, H 4.79%, N
16.76%, O 12.23%, S 15.72% (4) Ultraviolet absorption spectrum: lambda maximum (nm) methanol 203 309 221 221 350 (shoulder) 245 (shoulder) methanol-hydrochloric acid 205 308 222 222 353 (shoulder) 250 (shoulder) Methanol-sodium hydroxide 205 310 221 353 (shoulder) 250 (shoulder).

【0045】(5) 赤外線吸収スペクトル(KBr法):
3300,3120,2980,1660,1550,
1500,1250,990,940,760 cm-1 (6) 安定性:室温、pH2〜9で安定 (7) 比旋光度:〔α〕D 28=+133°(c 0.74
5,ジメチルスルホキシド) (8) 酸性、中性、塩基性の区分:塩基性物質 (9) 分子量:1182.44 (10)分子式:C50518 156
(5) Infrared absorption spectrum (KBr method):
3300, 3120, 2980, 1660, 1550,
1500, 1250, 990, 940, 760 cm -1 (6) Stability: Stable at room temperature and pH 2-9 (7) Specific rotation: [α] D 28 = + 133 ° (c 0.74
5, dimethyl sulfoxide) (8) Acidic, neutral, basic classification: basic substance (9) molecular weight: 1182.44 (10) molecular formula: C 50 H 51 O 8 N 15 S 6

【0046】抗生物質MI481−42F4−Aの生物
学的性質は次のとおりである。抗生物質MI481−4
2F4−Aの栄養寒天培地上での各種細菌に対する発育
阻止濃度(寒天平板希釈法による)を表1に示す。表1
より明らかなように抗生物質MI481−42F4−A
はグラム陽性菌に対して強い抗菌活性を有していた。ま
たメチシリン耐性黄色ブドウ球菌スタフィロコッカス、
アウレウス MS9610(MRSA)などの多剤耐性
菌の生育も強く阻止した。
The biological properties of the antibiotic MI481-42F4-A are as follows. Antibiotic MI481-4
Table 1 shows the inhibitory concentration of 2F4-A on various agars on a nutrient agar medium (by agar plate dilution method). Table 1
More clearly the antibiotic MI481-42F4-A
Had a strong antibacterial activity against Gram-positive bacteria. Also methicillin-resistant Staphylococcus aureus Staphylococcus,
It also strongly inhibited the growth of multidrug-resistant bacteria such as Aureus MS9610 (MRSA).

【0047】 [0047]

【0048】 [0048]

【0049】 [0049]

【0050】また、マウスで実施した急性毒性試験によ
ると、抗生物質MI481−42F4−AのLD50は、
腹腔内投与では100mg/kg以上であった。
According to the acute toxicity test conducted in mice, the LD 50 of the antibiotic MI481-42F4-A was
The intraperitoneal dose was 100 mg / kg or more.

【0051】さらに、マウスでの感染治療実験において
治療効果が確認された。1群5匹の雌CDF1 マウスに
黄色ブドウ球菌(S.aureus Smith)3.8×107 個/
mlとムチン(ジッコ)10%溶液を等量混合しマウス
1匹当り9.5×106 個を腹腔内に接種し感染させ
た。一方、本発明の抗生物質MI481−42F4−A
10.3mgを350μlのジメチルスルホキシド(D
MSO)に溶解し、Tween 80を微量加えさらに
生理食塩水を添加した後、腹腔内に感染直後及び4時間
後に一回ずつ投与した。
Further, a therapeutic effect was confirmed in an infection treatment experiment in mice. Staphylococcus aureus (S. aureus Smith) 3.8 × 10 7 cells / group in 5 female CDF 1 mice / group
ml and 10% mucin (Dicco) solution were mixed in equal amounts, and 9.5 × 10 6 mice per mouse were inoculated intraperitoneally for infection. On the other hand, the antibiotic MI481-42F4-A of the present invention
10.3 mg of 350 μl of dimethyl sulfoxide (D
After dissolving in MSO), a small amount of Tween 80 was added, and physiological saline was further added, and then intraperitoneally administered once immediately after the infection and 4 hours after the infection.

【0052】約20時間後に生死で判定した結果、本薬
剤のED80は0.6mg/kg以上であった。以上よ
り、抗生物質MI481−42F4−Aは人、動物の細
菌感染症の治療に用いられる可能性がある。
As a result of life and death judgment after about 20 hours, the ED 80 of this drug was 0.6 mg / kg or more. From the above, the antibiotic MI481-42F4-A may be used for treating bacterial infections in humans and animals.

【0053】以上のとおり、抗生物質MI481−42
F4−Aの理化学的性状並びに生物学的性質について詳
述したが、このような性質に類似した化合物は従来知ら
れていないので、抗生物質MI481−42F4−Aは
新規物質である。
As described above, the antibiotic MI481-42
Although the physicochemical properties and biological properties of F4-A have been described in detail, the antibiotic MI481-42F4-A is a novel substance because no compound similar to such properties has been known so far.

【0054】[0054]

【実施例】次に本発明を実施例により説明するが、本発
明はこれに限定されるものではない。
EXAMPLES The present invention will now be described with reference to examples, but the present invention is not limited thereto.

【0055】実施例1 グリセロール2.0%、デキストリン(和光純薬工)2
0%、ポリペプトン(和光純薬工)1.0%、酵母エキ
ス(和光純薬工)0.3%、硫酸アンモニウム0.2
%、炭酸カルシウム0.2%、消泡剤(KM70、信越
化学)0.01%を含む培地(pH7.4)110ml
を500ml容ワッフル付き三角フラスコに入れ、12
0℃で20分間滅菌後、これに寒天斜面上に生育したア
ミコラトプシス属に属するMI481−42F4株(F
ERM P−12739)を1白金耳接種し、27℃で
3日間振とう培養して得られた培養液を接種源とした。
上記と同じ培地にこの接種源2mlを移植し、27℃で
4日間培養し、抗生物質MI481−42F4−Aを蓄
積せしめた。
Example 1 2.0% glycerol, dextrin (Wako Pure Chemical Industries) 2
0%, polypeptone (Wako Pure Chemical Industries) 1.0%, yeast extract (Wako Pure Chemical Industries) 0.3%, ammonium sulfate 0.2
%, Calcium carbonate 0.2%, defoamer (KM70, Shin-Etsu Chemical) 0.01%, medium (pH 7.4) 110 ml
In a 500 ml waffle Erlenmeyer flask,
After sterilization at 0 ° C. for 20 minutes, the MI481-42F4 strain (F belonging to the genus Amycolatopsis belonging to the genus Amycolatopsis (F
1 platinum loop of ERM P-12739) was inoculated, and the culture solution obtained by shaking culture at 27 ° C. for 3 days was used as an inoculum source.
2 ml of this inoculum was transplanted to the same medium as above and cultured at 27 ° C. for 4 days to accumulate the antibiotic MI481-42F4-A.

【0056】培養液(pH8.2、10.1 liter) を
遠心分離し菌体を集め、これをメタノール5 literで抽
出した。抽出液を濃縮メタノールを溜去後水5 literを
加え等量のブタノールで抽出し、濃縮後、メタノールを
加え沈殿物を集め乾燥物4.3gを得た。これをジメチ
ルホルムアミドに溶解し、ジメチルホルムアミドに懸濁
して詰めたセファデックスLH−20(ファルマシア)
(外径50φ×100mm)の塔にかけ、ジメチルホル
ムアミドでゲルろ過した。活性画分(Bacillus thermoph
ilus に対し抗菌活性を示す画分)を減圧濃縮後、これ
をジメチルホルムアミドに溶解し、ジメチルホルムアミ
ドに懸濁して詰めたトヨパールHW−40(トーソー)
(外径40φ×420mm)の塔にかけ、ジメチルホル
ムアミドでゲルろ過し活性画分を減圧濃縮乾燥し乾燥物
780mgを得た。
The culture broth (pH 8.2, 10.1 liter) was centrifuged to collect the cells, and this was extracted with 5 liters of methanol. The extract was evaporated to remove concentrated methanol, added with 5 liters of water and extracted with an equal amount of butanol. After concentration, methanol was added and the precipitate was collected to obtain 4.3 g of a dried product. This was dissolved in dimethylformamide, suspended in dimethylformamide, and packed into Sephadex LH-20 (Pharmacia).
It was put in a column (outer diameter 50φ × 100 mm) and gel-filtered with dimethylformamide. Active fraction ( Bacillus thermoph
Fractions showing antibacterial activity against ilus ) were concentrated under reduced pressure, dissolved in dimethylformamide, suspended in dimethylformamide and packed into Toyopearl HW-40 (Tosoh).
The mixture was placed in a column (outer diameter 40φ × 420 mm), subjected to gel filtration with dimethylformamide, and the active fraction was concentrated and dried under reduced pressure to obtain 780 mg of a dried product.

【0057】これを15mlのクロロホルムに溶解し、
この溶液をシリカゲル(メルクArt.7734)25
gをクロロホルムに懸濁して詰めた塔にチャージし、塔
を200mlのクロロホルムで洗浄後、クロロホルム/
メタノール=10/1の混液で溶出し活性画分を集め、
減圧濃縮乾固し、純粋な抗生物質MI481−42F4
−Aの無色粉末232mgを得た。
This was dissolved in 15 ml of chloroform,
This solution was added to silica gel (Merck Art. 7734) 25
g was suspended in chloroform and charged into a packed column, and the column was washed with 200 ml of chloroform and then washed with chloroform /
Elute with a mixed solution of methanol = 10/1, collect active fractions,
Concentrated to dryness under reduced pressure and pure antibiotic MI481-42F4
232 mg of colorless powder of -A was obtained.

【0058】実施例2 30 liter容発酵槽に実施例1で用いた培地12 liter
を入れ、120℃20分間滅菌後、実施例1で用いた種
培養液100mlを接種し、27℃、72時間、通気量
12 liter/分、攪拌回転数200回/分で通気攪拌培
養した。以下実施例1と同様に抽出、精製し、MI48
1−42F4−Aの82mgを得た。
Example 2 12 liter of the medium used in Example 1 in a 30 liter fermentor
After sterilizing at 120 ° C. for 20 minutes, 100 ml of the seed culture solution used in Example 1 was inoculated, and aeration and stirring culture was carried out at 27 ° C. for 72 hours at an aeration rate of 12 liter / minute and a stirring rotation speed of 200 times / minute. Thereafter, extraction and purification were performed in the same manner as in Example 1, and MI48
82 mg of 1-42F4-A was obtained.

【0059】[0059]

【発明の効果】以上詳細に説明した通り、本発明により
新規抗生物質及びその製造方法が提供された。
As described above in detail, the present invention provides a novel antibiotic and a method for producing the same.

【図面の簡単な説明】[Brief description of drawings]

【図1】抗生物質MI481−42F4−Aの紫外線吸
収スペクトルを示している。
1 shows the UV absorption spectrum of the antibiotic MI481-42F4-A.

【図2】抗生物質MI481−42F4−Aの赤外線吸
収スペクトル(KBr法)を表わす。
FIG. 2 shows an infrared absorption spectrum (KBr method) of antibiotic MI481-42F4-A.

【図3】重ジメチルスルホキシド中で400MHzにお
いて測定した抗生物質MI481−42F4−Aの 1
−NMRスペクトルを表わす。
FIG. 3: 1 H of antibiotic MI481-42F4-A measured at 400 MHz in deuterated dimethyl sulfoxide.
Represents the NMR spectrum.

【図4】重ジメチルスルホキシド中で100MHzにお
いて測定した抗生物質MI481−42F4−Aの13
−NMRスペクトルを表わす。
FIG. 4: 13 C of antibiotic MI481-42F4-A measured in deuterated dimethyl sulfoxide at 100 MHz.
Represents the NMR spectrum.

─────────────────────────────────────────────────────
─────────────────────────────────────────────────── ───

【手続補正書】[Procedure amendment]

【提出日】平成4年7月1日[Submission date] July 1, 1992

【手続補正1】[Procedure Amendment 1]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0008[Correction target item name] 0008

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0008】MI481−42F4株の菌学的性状 1.形態 よく分枝した基生菌糸は、しばしばジグザグ状を呈し、
また分断が認められる。気菌糸は直状あるいは不規則な
曲状で、分断を認め、円筒形の胞子を形成する。胞子の
大きさは約0.6〜0.7×0.7〜1.2ミクロン
で、表面は平滑である。らせん形成、輪生枝および胞子
のうは認められない。
Mycological properties of MI481-42F4 strain 1. Morphology Well-branched basal hyphae often have a zigzag shape,
In addition, division is recognized. The aerial hyphae are straight or irregularly curved, with fragmentation, forming cylindrical spores. The size of the spores is about 0.6 to 0.7 × 0.7 to 1.2 microns, the surface is smooth. No helix formation, limbus or sporangia are observed.

【手続補正2】[Procedure Amendment 2]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0013[Correction target item name] 0013

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0013】(4)スターチ・無機塩寒天培地(ISP
−培地4、30℃培養) うす黄[1 1/2 ic, Lt Antique Gold 2gc, Bamboo ]
の発育上に白の気菌糸をうっすらと着生し、溶解性色素
は認められない。
(4) Starch / inorganic salt agar medium (ISP
-Medium 4, culture at 30 ℃) Light yellow [1 1/2 ic, Lt Antique Gold ~ 2gc, Bamboo]
White aerial hyphae grew slightly on the growth of the, and no soluble pigment was observed.

【手続補正3】[Procedure 3]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0015[Correction target item name] 0015

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0015】(6)栄養寒天培地(30℃培養) うす[2 gc, Bamboo]の発育上に、白の気菌糸をうっ
すらと着生し、溶解性色素は認められない。
(6) Nutrient agar medium (cultured at 30 ° C.) On the development of light yellow [2 gc, Bamboo], white aerial mycelia are slightly grown and no soluble pigment is observed.

【手続補正4】[Procedure amendment 4]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0020[Correction target item name] 0020

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0020】(11)リンゴ酸石灰寒天培地(30℃培
養) うす黄[1 ga, Lt Lemon Yellow ]の発育上に、白の気
菌糸をわずかに着生し、溶解性色素は認められない。
(11) Lime malate agar medium (cultured at 30 ° C.) On the development of light yellow [1 ga , Lt Lemon Yellow], white aerial mycelium slightly colonized and no soluble pigment was observed.

【手続補正5】[Procedure Amendment 5]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0026[Correction target item name] 0026

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0026】(3)スターチの加水分解(スターチ・無
機塩寒天培地およびスター寒天培地、いずれも30℃
培養) いずれの培地においても培養後6日目頃より水解性が認
められ、その作用は中等度である。
[0026] (3) Hydrolysis of starch (starch-inorganic salt agar medium and star Ji agar, both 30 ° C.
Cultivation) In any medium, water-decomposability was observed around the 6th day after culturing, and its action was moderate.

【手続補正6】[Procedure Amendment 6]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0033[Name of item to be corrected] 0033

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0033】以上の性状を要約すると、MI481−4
2F4株は、その形態上、基生菌糸はしばしばジグザグ
状を呈し、分断を認める。気菌糸は直状あるいは不規則
な曲状で、分断を認め、円筒形の胞子を形成し、その表
面は平滑である。らせん形成、輪生枝及び胞子のうは認
められない。種々の培地で、うす黄〜黄の発育上に白〜
うす黄の気菌糸を着生し、溶解性色素はわずかに黄色味
を帯びるか、又は認められない。メラニン様色素の生成
は陰性、スターチの水解性は中等度、硝酸塩の還元反応
は陽性であり、蛋白分解力は中等度である。
Summarizing the above properties, MI 481 -4
In the 2F4 strain, the basal hypha often show a zigzag shape due to its morphology, and fragmentation is observed. The aerial mycelium is straight or irregularly curved, with fragmentation, forming cylindrical spores, and its surface is smooth. No helix formation, limbal branch or sporangium is observed. In various media, light yellow ~ white on the development of yellow ~
The pale yellow aerial hyphae are settled, and the soluble pigment is slightly yellowish or absent. The formation of melanin-like pigment is negative, the water-degradability of starch is moderate, the reduction reaction of nitrate is positive, and the proteolytic activity is moderate.

【手続補正7】[Procedure Amendment 7]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0034[Correction target item name] 0034

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0034】ところで、MI481−42F4株の菌体
成分は、細胞壁に含まれる2,6−ジアミノピメリン酸
がメソ型であり、全菌体中の還元糖はアラビノース、ガ
ラクトースを含むA型である。また、ミコール酸を含ま
ず、リン脂質はPII型(ホスファチジルエタノールアミ
ンを含みホスファチジルコリン及び未知のグルコサミン
含有リン脂質を含まない)、主要なメナキノンはMK−
9(H4 )であり、MK−9(H2 )も認められた。
By the way, in the bacterial cell component of the MI481-42F4 strain, 2,6-diaminopimelic acid contained in the cell wall is meso-type, and the reducing sugar in all the bacterial cells is A-type containing arabinose and galactose. In addition, mycolic acid is not included, phospholipids are P type II (containing phosphatidylethanolamine and not phosphatidylcholine and unknown glucosamine-containing phospholipids), and the major menaquinone is MK-.
9 (H 4 ) and MK-9 (H 2 ) was also recognized.

【手続補正8】[Procedure Amendment 8]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0035[Correction target item name] 0035

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0035】以上の結果より、MI481−42F4株
は、アミコラトプシス(Amycolatop sis ,文献,Intern
ational Journal of Systematic Bacteriology,36
巻,29−37頁,198年)属に属するものと考え
られる。アミコラトプシス属の既知菌種を検索すると、
アミコラトプシス・オリエンタリス(Amycolatopsis or
ientalis,文献1,同上;文献2,International Jour
nal of Systematic Bactriology ,37巻,292−
295頁,1987年)及びアミコラトプシス・メディ
テラネイ(Amycolatopsis mediterranei,文献1及び
2,同上)が、近縁の種としてあげられた。
[0035] From the above results, MI481-42F4 strain, Amycolatopsis (Amycolatop sis, literature, Intern
ational Journal of Systematic Bacteriology, 36
, Pp. 29-37, is considered to belong to 198 six years) genus. Searching for known species of the genus Amycolatopsis,
Amycolatopsis orientalis ( Amycolatopsis or
ientalis , Reference 1, Ibid; Reference 2, International Jour
nal of Systematic Bact e riology, 37, pp. 292-
295, 1987) and Amycolatopsis mediterranei (References 1 and 2, ibid.) Were mentioned as closely related species.

【手続補正9】[Procedure Amendment 9]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0038[Correction target item name] 0038

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0038】本発明に用いることのできる菌株は上記菌
株、その変異株をはじめ、アミコラトプシス属に属する
MI48−42F4−A生産菌のすべてが使用でき
る。
The strains usable in the present invention is the strain, including its mutants, all MI48 1 -42F4-A producing bacteria belonging to the genus Amycolatopsis can be used.

【手続補正10】[Procedure Amendment 10]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0039[Correction target item name] 0039

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0039】本発明の抗生物質MI481−42F4−
は、上記菌株を抗生物質MI481−42F4−A生
産に適した培地に接種し培養することにより生産され
る。培地としては、通常の放線菌の培養に用いられる栄
養源含有培地でよい。
Antibiotics of the present invention MI481-42F4-
A is produced by inoculating the above strain into a medium suitable for the production of the antibiotic MI481-42F4-A and culturing. The medium may be a nutrient-source-containing medium used for usual actinomycete culture.

【手続補正11】[Procedure Amendment 11]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0044[Correction target item name] 0044

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0044】(1) 色と形状:無色粉末 (2) 融点:294−295℃(分解) (3) 元素分析:C 49.46%,H 4.79%,N
16.76%, O 12.23%,S 15.72% (4) 紫外線吸収スペクトル: ラムダ最大(nm) メタノール 203 309 221 350(肩) 245(肩) メタノール−塩酸 205 308 222 353(肩) 250(肩) メタノール−水酸化ナトリウム 205 310 221 353(肩) 250(肩
(1) Color and shape: colorless powder (2) Melting point: 294-295 ° C (decomposition) (3) Elemental analysis: C 49.46%, H 4.79%, N
16.76%, O 12.23%, S 15.72% (4) Ultraviolet absorption spectrum: lambda maximum (nm) methanol 203 309 221 221 350 (shoulder) 245 (shoulder) methanol-hydrochloric acid 205 308 222 222 353 (shoulder) 250 (shoulder) Methanol-sodium hydroxide 205 310 221 353 (shoulder) 250 (shoulder )

【手続補正12】[Procedure Amendment 12]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0046[Correction target item name] 0046

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0046】抗生物質MI481−42F4−Aの生物
学的性質は次のとおりである。抗生物質MI481−4
2F4−Aの栄養寒天培地上での各種細菌に対する発育
阻止濃度(寒天平板希釈法による)を表1に示す。表1
より明らかなように抗生物質MI481−42F4−A
はグラム陽性菌に対して強い抗菌活性を有していた。ま
たメチシリン耐性黄色ブドウ球菌スタフィロコッカス
アウレウス MS9610(MRSA)などの多剤耐性
菌の生育も強く阻止した。
The biological properties of the antibiotic MI481-42F4-A are as follows. Antibiotic MI481-4
Table 1 shows the inhibitory concentration of 2F4-A on various agars on a nutrient agar medium (by agar plate dilution method). Table 1
More clearly the antibiotic MI481-42F4-A
Had a strong antibacterial activity against Gram-positive bacteria. The methicillin-resistant Staphylococcus aureus Staphylococcus
It also strongly inhibited the growth of multidrug-resistant bacteria such as Aureus MS9610 (MRSA).

【手続補正13】[Procedure Amendment 13]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0047[Correction target item name] 0047

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0047】 [0047]

【手続補正14】[Procedure Amendment 14]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0048[Correction target item name] 0048

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0048】 [0048]

【手続補正15】[Procedure Amendment 15]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0049[Correction target item name] 0049

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0049】 [0049]

【手続補正16】[Procedure 16]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0051[Correction target item name] 0051

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0051】さらに、マウスでの感染治療実験において
治療効果が確認された。1群5匹の雌CDF1 マウスに
黄色ブドウ球菌(S.aureus Smith)3.8×107 個/
mlとムチン(ジコ)10%溶液を等量混合しマウス
1匹当り9.5×106 個を腹腔内に接種し感染させ
た。一方、本発明の抗生物質MI481−42F4−A
10.3mgを350μlのジメチルスルホキシド(D
MSO)に溶解し、Tween 80を微量加えさらに
生理食塩水を添加した後、腹腔内に感染直後及び4時間
後に一回ずつ投与した。
Further, a therapeutic effect was confirmed in an infection treatment experiment in mice. Staphylococcus aureus (S. aureus Smith) 3.8 × 10 7 cells / group in 5 female CDF 1 mice / group
ml and mucin (di off co) 10% solution mixed in equal amounts to 9.5 × 10 6 cells per pet mice were allowed inoculated infected intraperitoneally. On the other hand, the antibiotic MI481-42F4-A of the present invention
10.3 mg of 350 μl of dimethyl sulfoxide (D
After dissolving in MSO), a small amount of Tween 80 was added, and physiological saline was further added, and then intraperitoneally administered once immediately after the infection and 4 hours after the infection.

【手続補正17】[Procedure Amendment 17]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0055[Correction target item name] 0055

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0055】実施例1 グリセロール2.0%、デキストリン(和光純薬工)
2.0%、ポリペプトン(和光純薬工)1.0%、酵母
エキス(和光純薬工)0.3%、硫酸アンモニウム0.
2%、炭酸カルシウム0.2%、消泡剤(KM70、信
越化学)0.01%を含む培地(pH7.4)110m
lを500ml容ワッフル付き三角フラスコに入れ、1
20℃で20分間滅菌後、これに寒天斜面上に生育した
アミコラトプシス属に属するMI481−42F4株
(FERM P−12739)を1白金耳接種し、27
℃で3日間振とう培養して得られた培養液を接種源とし
た。上記と同じ培地にこの接種源2mlを移植し、27
℃で4日間培養し、抗生物質MI481−42F4−A
を蓄積せしめた。
Example 1 Glycerol 2.0%, dextrin (Wako Pure Chemical Industries)
2.0 %, polypeptone (Wako Pure Chemical Industries) 1.0%, yeast extract (Wako Pure Chemical Industries) 0.3%, ammonium sulfate 0.
Medium (pH 7.4) 110m containing 2%, calcium carbonate 0.2%, and antifoaming agent (KM70, Shin-Etsu Chemical) 0.01%
1 is put into a 500 ml waffle Erlenmeyer flask and 1
After sterilization at 20 ° C. for 20 minutes, 1 platinum loop of MI481-42F4 strain (FERM P-12739) belonging to the genus Amycolatopsis grown on the agar slope was inoculated, and
A culture solution obtained by shaking culture at 3 ° C. for 3 days was used as an inoculum source. 2 ml of this inoculum was transferred to the same medium as above, and 27
Cultivated at 4 ° C for 4 days and antibiotic MI481-42F4-A
Accumulated.

【手続補正18】[Procedure 18]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0056[Correction target item name] 0056

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0056】培養液(pH8.2、10.1 liter) を
遠心分離し菌体を集め、これをメタノール5 literで抽
出した。抽出液を濃縮メタノールを溜去後水5 lit
erを加え等量のブタノールで抽出し、濃縮後、メタノー
ルを加え沈殿物を集め乾燥物4.3gを得た。これをジ
メチルホルムアミドに溶解し、ジメチルホルムアミドに
懸濁して詰めたセファデックスLH−20(ファルマシ
ア)(外径50φ×1000mm)の塔にかけ、ジメチ
ルホルムアミドでゲルろ過した。活性画分(Bacillus t
hermophilus に対し抗菌活性を示す画分)を減圧濃縮
後、これをジメチルホルムアミドに溶解し、ジメチルホ
ルムアミドに懸濁して詰めたトヨパールHW−40(ト
ーソー)(外径40φ×420mm)の塔にかけ、ジメ
チルホルムアミドでゲルろ過し活性画分を減圧濃縮乾燥
し乾燥物780mgを得た。
The culture broth (pH 8.2, 10.1 liter) was centrifuged to collect the cells, and this was extracted with 5 liters of methanol. After concentrating the extract and distilling off methanol , water 5 lit
er was added, the mixture was extracted with an equal amount of butanol, concentrated, and then methanol was added to collect the precipitate to obtain 4.3 g of a dried product. This was dissolved in dimethylformamide, suspended in dimethylformamide and packed in a packed Sephadex LH-20 (Pharmacia) (outer diameter 50φ × 1000 mm) column, and gel filtered with dimethylformamide. Active fraction ( Bacillus t
(Fraction exhibiting antibacterial activity against hermophilus ) was concentrated under reduced pressure, dissolved in dimethylformamide, suspended in dimethylformamide and applied to a Toyopearl HW-40 (tosaw) (outer diameter 40φ × 420 mm) tower, and dimethylformamide was added. Gel filtration was performed with formamide, and the active fraction was concentrated and dried under reduced pressure to obtain 780 mg of a dried product.

【手続補正19】[Procedure Amendment 19]

【補正対象書類名】明細書[Document name to be amended] Statement

【補正対象項目名】0058[Correction target item name] 0058

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【0058】実施例2 30 liter容発酵槽に実施例1で用いた培地12 liter
を入れ、120℃20分間滅菌後、実施例1で用いた種
培養液100mlを接種し、27℃、72時間、通気量
12 liter/分、攪拌回転数200回/分で通気攪拌培
養した。以下実施例1と同様に抽出、精製し、MI48
1−42F4−A82mg得た。
Example 2 12 liter of the medium used in Example 1 in a 30 liter fermentor
After sterilizing at 120 ° C. for 20 minutes, 100 ml of the seed culture solution used in Example 1 was inoculated, and aeration and stirring culture was carried out at 27 ° C. for 72 hours at an aeration rate of 12 liter / minute and a stirring rotation speed of 200 times / minute. Thereafter, extraction and purification were carried out in the same manner as in Example 1 to obtain MI48.
82 mg of 1-42F4-A was obtained .

【手続補正20】[Procedure amendment 20]

【補正対象書類名】図面[Document name to be corrected] Drawing

【補正対象項目名】図1[Name of item to be corrected] Figure 1

【補正方法】変更[Correction method] Change

【補正内容】[Correction content]

【図1】 [Figure 1]

フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 //(C12P 1/02 C12R 1:645) (72)発明者 飯沼 寛信 埼玉県和光市白子3丁目35番6−301号 住友和光ハウス (72)発明者 嶋中 一夫 東京都大田区西蒲田3丁目4番7−301号Continuation of the front page (51) Int.Cl. 5 Identification number Reference number within the agency FI technical display area // (C12P 1/02 C12R 1: 645) (72) Inventor Hironobu Iinuma 3-35 Shiroko, Wako-shi, Saitama No. 6-301 Sumitomo Wako House (72) Inventor Kazuo Shimanaka 3-4-7-301 Nishi-Kamata, Ota-ku, Tokyo

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 下記の特性: (1) 色と形状:無色粉末 (2) 融点:294−295℃(分解) (3) 元素分析:C 49.46%,H 4.79%,N
16.76%, O 12.23%,S 15.72% (4) 紫外線吸収スペクトル: ラムダ最大(nm) メタノール 203 309 221 350(肩) 245(肩) メタノール−塩酸 205 308 222 353(肩) 250(肩) メタノール−水酸化ナトリウム 205 310 221 353(肩) 250(肩) (5) 赤外線吸収スペクトル(KBr法):3300,3
120,2980,1660,1550,1500,1
250,990,940,760 cm-1 (6) 安定性:室温、pH2〜9で安定 (7) 比旋光度:〔α〕D 28=+133°(c 0.74
5,ジメチルスルホキシド) (8) 酸性、中性、塩基性の区分:塩基性物質 (9) 分子量:1182.44 (10)分子式:C50518 156 を有することを特徴とする新規抗生物質MI481−4
2F4−A。
1. The following characteristics: (1) Color and shape: colorless powder (2) Melting point: 294-295 ° C. (decomposition) (3) Elemental analysis: C 49.46%, H 4.79%, N
16.76%, O 12.23%, S 15.72% (4) Ultraviolet absorption spectrum: lambda maximum (nm) methanol 203 309 221 221 350 (shoulder) 245 (shoulder) methanol-hydrochloric acid 205 308 222 222 353 (shoulder) 250 (shoulder) methanol-sodium hydroxide 205 310 221 353 (shoulder) 250 (shoulder) (5) Infrared absorption spectrum (KBr method): 3300,3
120, 2980, 1660, 1550, 1500, 1
250,990,940,760 cm -1 (6) Stability: Stable at room temperature and pH 2-9 (7) Specific rotation: [α] D 28 = + 133 ° (c 0.74
5, dimethylsulfoxide) (8) Acidic, neutral, basic classification: basic substance (9) molecular weight: 1182.44 (10) molecular formula: C 50 H 51 O 8 N 15 S 6 New antibiotic MI481-4
2F4-A.
【請求項2】 アミコラトプシス属に属するMI481
−42F4−A生産菌を培養し、その培養物から新規抗
生物質MI481−42F4−Aを分離採取することを
特徴とする新規抗生物質MI481−42F4−Aの製
造方法。
2. MI481 belonging to the genus Amycolatopsis
A method for producing a novel antibiotic MI481-42F4-A, which comprises culturing a -42F4-A producing bacterium, and separating and collecting the novel antibiotic MI481-42F4-A from the culture.
JP04142045A 1992-05-08 1992-05-08 New antibiotic MI481-42F4-A and method for producing the same Expired - Fee Related JP3107455B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP04142045A JP3107455B2 (en) 1992-05-08 1992-05-08 New antibiotic MI481-42F4-A and method for producing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP04142045A JP3107455B2 (en) 1992-05-08 1992-05-08 New antibiotic MI481-42F4-A and method for producing the same

Publications (2)

Publication Number Publication Date
JPH05310766A true JPH05310766A (en) 1993-11-22
JP3107455B2 JP3107455B2 (en) 2000-11-06

Family

ID=15306116

Family Applications (1)

Application Number Title Priority Date Filing Date
JP04142045A Expired - Fee Related JP3107455B2 (en) 1992-05-08 1992-05-08 New antibiotic MI481-42F4-A and method for producing the same

Country Status (1)

Country Link
JP (1) JP3107455B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003516389A (en) * 1999-12-08 2003-05-13 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Amicomycin, its production process and its use as a medicament
WO2004081036A1 (en) * 2003-03-11 2004-09-23 Asahi Kasei Pharma Corporation Peptidic antibiotic
CN1325656C (en) * 1998-11-09 2007-07-11 萨诺费-阿文蒂斯德国有限公司 Vancoresmycin, a process for its production and its use as a pharmaceutical

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1325656C (en) * 1998-11-09 2007-07-11 萨诺费-阿文蒂斯德国有限公司 Vancoresmycin, a process for its production and its use as a pharmaceutical
JP2003516389A (en) * 1999-12-08 2003-05-13 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Amicomycin, its production process and its use as a medicament
JP4750993B2 (en) * 1999-12-08 2011-08-17 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Amicomycin, its production process and its use as a pharmaceutical
WO2004081036A1 (en) * 2003-03-11 2004-09-23 Asahi Kasei Pharma Corporation Peptidic antibiotic

Also Published As

Publication number Publication date
JP3107455B2 (en) 2000-11-06

Similar Documents

Publication Publication Date Title
KR900004066B1 (en) Process for the preparation of biologically active ws 6049
FR2466471A1 (en) ANTIBIOTIC NEW, PROCESS FOR PRODUCING THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
US5484717A (en) Antibiotic 31F508α1, 31F508α2, 31F508β1, 31F508β2
US4973552A (en) Staurosporine fermentation process
JPH05310766A (en) New antibiotic substance mi481-42f4-a and its produciton
JP2833181B2 (en) FR901375 substance and production method thereof
US4550021A (en) Antitumor antibiotic 81-484 and process for its production
US4393056A (en) Antibiotics tetronolide compounds and process for production thereof
JP2592468B2 (en) Benanomycins A and B, novel antibiotics and their production
JP3327982B2 (en) New antibiotic MI481-42F4-A related substance
JPH05117298A (en) Depsipeptide a and b, its production, anti-virus agent and antibacterial agent
JP3067322B2 (en) Method for producing 3'-hydroxybenanomycin A, an antifungal antibiotic
JPS6015318B2 (en) New antibiotic SF-1942 substance, its manufacturing method and anticancer agent containing it
KR840000934B1 (en) Process for preparing antibiotic sf-2080 a and sf-2080 b
JPH05146298A (en) Production of 3-hydroxy-2-methyl-4-pyridone
JPH07215989A (en) New antibiotic substance mi481-42f-a related substance and its production
JPH10114777A (en) Antibiotic substance spiroximicin and its production
FR2463618A1 (en) NOVEL ANTIBIOTIC AMINOGLYCOSIDE AND ITS PRODUCTION
JPH09157266A (en) New antibiotic epoxynomicin a and b and their production
JPH0515385A (en) Novel antibiotic allithamycin and method for its production
JP2007131552A (en) Novel antibiotic sf2856 substance, its production method, and pharmaceutical composition
JPS60192593A (en) Fr-900462 substance
JPS60130394A (en) Novel antibiotic sf-2324 substance, preparation, and use thereof
JPH03262490A (en) New antibiotic bmh 829-af1 and production thereof
JPH0565297A (en) Enopeptin a, its production and antiviral agent

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20070908

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080908

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090908

Year of fee payment: 9

LAPS Cancellation because of no payment of annual fees